Real‐life data on basal cell carcinoma treatment: Insights on clinicians' therapeutic choices from an institutional hospital registry

Manoli, Sofia-Magdalini; Moutsoudis, Andreas; Papageorgiou, Chryssoula; Lallas, Konstantinos; Rigas, Haris-Marios; Kyrmanidou, Eirini; Papadimitriou, Ilias; Paschou, Eleni; Spyridis, Ioannis; Gkentsidi, Theodosia; Sotiriou, Elena; Vakirlis, Efstratios; Ioannidis, Demetrios; Apalla, Zoe; Lallas, Aimilios

doi:10.1111/dth.14414

Cited by 3 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surgery is the most frequently applied BCC treatment, but nonsurgical modalities do also have an essential role in clinical practice 52 . Further studies are required to confirm the fundamental role of the combination of IFN alpha and gamma in the effective control of BCC tumor growth in the real world environment.…”

Section: Discussionmentioning

confidence: 99%

Basal cell carcinoma treated with HeberFERON. A real world retrospective study

C¹,

Roben-Aguilar

Reyes-Acosta

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Basal cell carcinoma is the most common type of skin cancer with major impact in health-related quality of life. The use of the formulation based on the combination of IFN-alpha 2b and IFN-gamma (HeberFERON) is an effective alternative in the treatment of basal cell carcinoma, immunogenic tumor, potentially responsible to immunotherapies. The aim of this report is to record, retrospectively, the effect of HeberFERON patients with BCC in the Cuban real word condition. Methods This is a retrospectively study of the use of HeberFERON in real world conditions. Eligible patients were adults with histologic diagnosis of single or multiple basal cell carcinoma of any skin phototype, lesions of any size, subtype, location, recurrent or not, with or without specific prior treatments. Adult patients, who signed the informed consent to receive the treatment with HeberFERON, were identified from the data bases. The evaluation of clinical effectiveness was carried out according to RECIST 1.1. Ethical committee of participating institutions approved the study. Results In clinical practice evaluated patients the nose was the region of higher frequency of tumors (36.3%) and the nodular clinical subtype was the predominant (45.3%). Clinical response rate differences (p=0. 000) were found, with complete response of 61.9%, and partial response of 32.7%; with an overall response rate of 94.2% The HeberFERON exerted a 100% disease control, with no progression reported in 640 treated patients. The best responder tumor subtypes to HeberFERON were the more aggressive tumors, morpheaform with complete response of 72% (overall response=96%), followed by the infiltrative with complete response of 66.7% (overall response=100%). Tumor with larger size and patients with more than four tumors had lesser response to the anti-tumor effect of HeberFERON. Conclusions HeberFERON was highly effective in basal cell carcinomas in real world conditions. In the context of resistance of skin tumors to hedgehog and immune check point inhibitors the combination of IFNs alpha 2b and IFN gamma appears as a plausible therapeutic option for a wide number of basal cell carcinomas.

show abstract

Section: Discussionmentioning

confidence: 99%

Basal cell carcinoma treated with HeberFERON. A real world retrospective study

C¹,

Roben-Aguilar

Reyes-Acosta

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

Uncertainty estimation for margin detection in cancer surgery using mass spectrometry

et al. 2022

View full text Add to dashboard Cite

A Review of Immunocryosurgery and a Practical Guide to Its Applications

Gaitanis

Bassukas

2021

Diseases

View full text Add to dashboard Cite

Immunocryosurgery is a minimally invasive combinational therapeutic procedure that has been designed, developed, and evaluated in the Dermatology Department of the University of Ioannina from 2004. In a fixed time protocol, this approach combines immune stimulatory therapy with imiquimod and cryosurgery, i.e., cryosurgery is applied during continuous imiquimod treatment. Laboratory findings in tissue and blood level credit the efficacy to the synergy of imiquimod and cryosurgery. The synergy has been established through clinical trials and the excellent feasibility and efficacy demonstrated in clinical practice. Immunocryosurgery has extensive proof of excellent efficacy, comparable to surgery, in the treatment of basal cell carcinoma. It has also been evaluated in cases of Bowen’s disease, keratoacanthoma, Merkel cell carcinoma, lentigo maligna, and cutaneous squamous cell carcinoma with or without the addition of adjuvants. The aims of this review are to detail the immunocryosurgery protocol with the addition of daily practice clinical tips, compile data on the mechanism of action of immunocryosurgery, and delineate indications and possible future applications. Most of the available data originate from the treatment of BCC, of all histological types and localizations, and the principles reported mainly reflect on evidence related to the treatment of this common skin cancer.

show abstract

Real‐life data on basal cell carcinoma treatment: Insights on clinicians' therapeutic choices from an institutional hospital registry

Cited by 3 publications

References 28 publications

Basal cell carcinoma treated with HeberFERON. A real world retrospective study

Basal cell carcinoma treated with HeberFERON. A real world retrospective study

Uncertainty estimation for margin detection in cancer surgery using mass spectrometry

A Review of Immunocryosurgery and a Practical Guide to Its Applications

Contact Info

Product

Resources

About